Abstract
Epithelial ovarian cancer is a leading cause of cancer-related death for women both in the United States and worldwide, and the effectiveness of cytotoxic chemotherapy has plateaued. Angiogenesis plays an important role in ovarian cancer biology, and exploration of anti-angiogenic agents in this disease has demonstrated anti-tumor activity both as monotherapy and in combination with cytotoxic chemotherapy. However, key questions remain regarding the use of these drugs in ovarian cancer, such as where in treatment should they be used, should these drugs be used as single agents or combined with chemotherapy, can and which biomarkers predict efficacy, are there efficacy and toxicity differences amongst the various agents, what are the cost-benefit ratios of these therapies, and are the patient outcome improvements observed in completed studies significant enough to warrant widespread use of these drugs? Here, we review recent progress and discuss ongoing controversies regarding the use of anti-angiogenic therapies in ovarian cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
